AstraZeneca to stop making Pulmicort inhaler; SkyePharma shares slump
This article was originally published in Scrip
Executive Summary
AstraZeneca's "unexpected" decision to stop manufacturing the Pulmicort (budesonide) pressurised metered dose inhaler (pMDI), for which SkyePharma developed the formulation, does not have any implications for SkyePharma's Flutiform (fluticasone propionate plus formoterol fumarate), which is currently being assessed by European regulators, SkyePharma CFO Peter Grant told Scrip.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.